255 related articles for article (PubMed ID: 23023583)
21. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
22. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
23. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
[TBL] [Abstract][Full Text] [Related]
24. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Stepensky D; Tzehoval E; Vadai E; Eisenbach L
Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
[TBL] [Abstract][Full Text] [Related]
25. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
26. Specificity clusters of MUC1-reactive mouse monoclonal antibodies.
Hanisch FG
Tumour Biol; 1998; 19 Suppl 1():111-7. PubMed ID: 9422095
[TBL] [Abstract][Full Text] [Related]
27. Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope.
Singh J; Her C; Supekar N; Boons GJ; Krishnan VV; Brooks CL
J Pept Sci; 2020 Jan; 26(1):e3229. PubMed ID: 31729101
[TBL] [Abstract][Full Text] [Related]
28. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
[TBL] [Abstract][Full Text] [Related]
29. Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
Matsushita T; Ohyabu N; Fujitani N; Naruchi K; Shimizu H; Hinou H; Nishimura S
Biochemistry; 2013 Jan; 52(2):402-14. PubMed ID: 23259747
[TBL] [Abstract][Full Text] [Related]
30. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
Price MR; Rye PD; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek MF; Snijdewint FG; von Mensdorff-Pouilly S; Verstraeten RA; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker MB; Hilgers J
Tumour Biol; 1998; 19 Suppl 1():1-20. PubMed ID: 9422084
[TBL] [Abstract][Full Text] [Related]
31. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity.
Westerlind U; Schröder H; Hobel A; Gaidzik N; Kaiser A; Niemeyer CM; Schmitt E; Waldmann H; Kunz H
Angew Chem Int Ed Engl; 2009; 48(44):8263-7. PubMed ID: 19718733
[No Abstract] [Full Text] [Related]
33. Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.
Seko A; Ohkura T; Ideo H; Yamashita K
Glycobiology; 2012 Feb; 22(2):181-95. PubMed ID: 21880669
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
35. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.
Wandall HH; Blixt O; Tarp MA; Pedersen JW; Bennett EP; Mandel U; Ragupathi G; Livingston PO; Hollingsworth MA; Taylor-Papadimitriou J; Burchell J; Clausen H
Cancer Res; 2010 Feb; 70(4):1306-13. PubMed ID: 20124478
[TBL] [Abstract][Full Text] [Related]
36. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
37. Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen.
Schuman J; Campbell AP; Koganty RR; Longenecker BM
J Pept Res; 2003 Mar; 61(3):91-108. PubMed ID: 12558945
[TBL] [Abstract][Full Text] [Related]
38. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat.
Takeuchi H; Kato K; Denda-Nagai K; Hanisch FG; Clausen H; Irimura T
J Immunol Methods; 2002 Dec; 270(2):199-209. PubMed ID: 12379325
[TBL] [Abstract][Full Text] [Related]
39. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
40. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
